New pill targets rare genetic cancers in first human trial
Disease control
Ongoing
This early-stage study tests an experimental pill called APS03118 in adults with advanced solid tumors that have specific RET gene mutations or fusions. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 108 participants will…
Phase: PHASE1 • Sponsor: Applied Pharmaceutical Science, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC